Abstract
After injury to the central nervous system (CNS) of adult vertebrates, axonal regeneration is extremely limited because inhibitory proteins existing around the injury site prevent the regrowth of the lesioned axons. Previous studies have reported that several myelin-derived proteins (such as Nogo, MAG, OMgp) and developmental guidance proteins (such as RGM, semaphorin, ephrin) contribute to the inhibition of axonal regeneration after injury in the adult CNS. Although each neurite growth inhibitory protein induces neurite retraction and growth cone collapse through specific receptors, they commonly utilize the function of small GTPases, including Rho, Rac, Cdc42, and Ras, that regulate neurite outgrowth by controlling actin and microtubule cytoskeleton. The small GTPase Rho and its effector Rho-kinase play critical roles in the induction of neurite retraction and growth cone collapse in vitro and the inhibition of axonal regeneration in vivo. Therefore, the Rho inhibitor C3 transferase and Rho-kinase inhibitors are thought to be effective therapeutic candidates involved in the promotion of axonal regeneration after human CNS injuries such as spinal cord injury.
Keywords: Small GTPase, Rho, Rho-kinase, actin, microtubule, CNS injury, axonal regeneration
Central Nervous System Agents in Medicinal Chemistry
Title: Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Volume: 7 Issue: 4
Author(s): Mitsuharu Endo and Toshihide Yamashita
Affiliation:
Keywords: Small GTPase, Rho, Rho-kinase, actin, microtubule, CNS injury, axonal regeneration
Abstract: After injury to the central nervous system (CNS) of adult vertebrates, axonal regeneration is extremely limited because inhibitory proteins existing around the injury site prevent the regrowth of the lesioned axons. Previous studies have reported that several myelin-derived proteins (such as Nogo, MAG, OMgp) and developmental guidance proteins (such as RGM, semaphorin, ephrin) contribute to the inhibition of axonal regeneration after injury in the adult CNS. Although each neurite growth inhibitory protein induces neurite retraction and growth cone collapse through specific receptors, they commonly utilize the function of small GTPases, including Rho, Rac, Cdc42, and Ras, that regulate neurite outgrowth by controlling actin and microtubule cytoskeleton. The small GTPase Rho and its effector Rho-kinase play critical roles in the induction of neurite retraction and growth cone collapse in vitro and the inhibition of axonal regeneration in vivo. Therefore, the Rho inhibitor C3 transferase and Rho-kinase inhibitors are thought to be effective therapeutic candidates involved in the promotion of axonal regeneration after human CNS injuries such as spinal cord injury.
Export Options
About this article
Cite this article as:
Endo Mitsuharu and Yamashita Toshihide, Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/187152407783220788
DOI https://dx.doi.org/10.2174/187152407783220788 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases
Current Pharmaceutical Design Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology
Current Neuropharmacology The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Current Pharmaceutical Design Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Voltage-Gated Sodium Channel Blockers for the Treatment of Chronic Pain
Current Topics in Medicinal Chemistry Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?
Current Medicinal Chemistry Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design